

**Exhibit 5-1****Examples of Combination Products**

<b>Product</b>	<b>Company</b>	<b>Year</b>

**INNOVATION TO COMMODITY*****The Medical Device Market Model***

Key to an understanding of the market for medical devices, is an understanding the cycle of innovation and commoditization of technology in the sector. This cycle has an impact on the business objectives, motivations and activities of market players, including a substantial impact on medical device distribution.

The U.S. Census Bureau noted in its “Global Population at a Glance: 2002 and Beyond” report that XX xxxx people inhabited the globe in 2002, with an annual growth rate of XX% (about XXXX people per day). However, the growth rate is XXXX significantly. Children comprised nearly XX% of the world’s population in 2002; by 2050, that percentage is expected to drop to XX%. On the other hand, the number of people 65 years of age and older is projected to XXX during the same time frame. Therefore, by 2050, the number of people over 65 will comprise of an estimated XX% of the population.

Accompanying that population shift is an increased need for products in sectors such as cardiovascular, Orthopedics, ophthalmics and interventional medicine.

\$XX xxxx in Asia). Currently, diagnostic testing accounts for only between XX-XX% of government healthcare expenditures worldwide, yet influences between XX-XX% of healthcare decisions. Cost is one of the key drivers in the strategic transfer of diagnostic testing from central laboratories into point-of-care settings.

In a new study from Kalorama Information covering Clinical Diagnostics in India, it is estimated that in-vitro diagnostics (IVD) revenues topped \$XX xxxx in 2006. The report describes the high growth IVD industry which has been averaging annual growth rates between XX% and XX%.

Due to favourable market factors, including new private insurance programs, a continuously expanding number of laboratories, and a healthy economy, the market is expected to continue to maintain its double-digit growth rates over the next three years.

The lion's share of the market comes from the routine chemistry segment which makes up XX% of the revenues. Immunochemistry diagnostics follow closely behind with a XX% market share. Availability of new tests and increased screening resulting from a greater understanding of lifestyle-related diseases and chronic disease management are helping to increase revenues and drive new trends in this evolving market.

There are two interesting trends that have already emerged which should be key to continued market growth. Large manufacturers are asserting more control over their distribution with several important international manufacturers establishing a business operation in India. The appearance of Chinese produced products in the market is just emerging and will provide increased availability of diagnostic tests.

The report provides essential historical perspectives from their 10+ years of on-the-ground primary research in the Asian IVD marketplace. Their comprehensive analysis examines India's market for IVD tests in the following market sectors: routine chemistry, critical care chemistry, haematology, urinalysis, coagulation, immunochemistry, and molecular testing.

Source: Kalorama Information

Growth in POC diagnostics has been made possible through advances in technology, automation and IT which have enabled the development of portable analytical equipment that is easy to use by non-laboratory staff and which offers reliable and reproducible results. In many hospitals, POC testing now accounts for XX% of diagnostic testing and has extended beyond the hospital to primary care